|
|
[Report]
BIOMARKERS - A MARKET INSIGHT REPORT
Published: 2008/01
|
|
 |
|
|
|
Table of Contents
I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
- 1. Introduction
- Biomarkers
- Segmentation of Biomarkers
- Exhibit 1: Segmentation of Global Biomarkers Market By Discovery
Technology (Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics
and Other) and Therapeutic Area (Oncology, Cardiology, Neurology and Other)
- 2. Global Market Analysis
- Exhibit 2: Biomarkers (2005-2012) - Global Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Therapeutic Area Analysis by Geographic Region
- Oncology
- Exhibit 3: Biomarkers in Oncology (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million
(Graphical Representation Included)
- Exhibit 4: Biomarkers in Oncology (2006, 2009 and 2012) - Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Japan, Asia-Pacific, Canada and Rest of World
- Cardiology
- Exhibit 5: Biomarkers in Cardiology (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million
(Graphical Representation Included)
- Exhibit 6: Biomarkers in Cardiology (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
(Graphical Representation Included)
- Neurology
- Exhibit 7: Biomarkers in Neurology (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million
(Graphical Representation Included)
- Exhibit 8: Biomarkers in Neurology (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
- Other
- Exhibit 9: Biomarkers in Other Therapeutics (2005-2012) - Global
Market Analysis (Current & Future) by Geographic Region for United
States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$
Million (Graphical Representation Included)
- Exhibit 10: Biomarkers in Other Therapeutics (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
- Biomarker Discovery Technology Analysis by Geographic Region
- Imaging
- Exhibit 11: Imaging Technologies for Biomarker Discovery (2005-2012)
- Global Market Analysis (Current & Future) by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in
US$ Million (Graphical Representation Included)
- Exhibit 12: Imaging Technologies for Biomarker Discovery (2006, 2009
and 2012) - Percentage Breakdown of Global Market Value by Geographic
Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest
of World (Graphical Representation Included)
- Genomics
- Exhibit 13: Genomic Technologies for Biomarker Discovery (2005-2012)
- Global Market Analysis (Current & Future) by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in
US$ Million(Graphical Representation Included)
- Exhibit 14: Genomic Technologies for Biomarker Discovery (2006, 2009
and 2012) - Percentage Breakdown of Global Market Value by Geographic
Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest
of World(Graphical Representation Included)
- Proteomics
- Exhibit 15: Proteomic Technologies for Biomarker Discovery
(2005-2012) - Global Market Analysis (Current & Future) by Geographic
Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest
of World in US$ Million (Graphical Representation Included)
- Exhibit 16: Proteomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of Global Market Value by
Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada
and Rest of World (Graphical Representation Included)
- Metabolomics
- Exhibit 17: Metabolomic Technologies for Biomarker Discovery
(2005-2012) - Global Market Analysis (Current & Future) by Geographic
Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest
of World in US$ Million (Graphical Representation Included)
- Exhibit 18: Metabolomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of Global Market Value by
Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada
and Rest of World (Graphical Representation Included)
- Bioinformatics
- Exhibit 19: Bioinformatics for Biomarker Discovery (2005-2012) -
Global Market Analysis (Current & Future) by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in
US$ Million (Graphical Representation Included)
- Exhibit 20: Bioinformatics for Biomarker Discovery (2006, 2009 and
2012) - Percentage Breakdown of Global Market Value by Geographic Region
for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
- Other
- Exhibit 21: Other Biomarker Discovery Technologies (2005-2012) -
Global Market Analysis (Current & Future) by Geographic Region for
United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in
US$ Million (Graphical Representation Included)
- Exhibit 22: Other Biomarker Discovery Technologies (2006, 2009 and
2012) - Percentage Breakdown of Global Market Value by Geographic Region
for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
- Exhibit 23: List of Major Global Companies
- 2. Regional Market Analysis
- North America
- Exhibit 24: Biomarkers (2005-2012) - North American Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Major Companies in North America
- Affymetrix, Inc. (USA)
- Agilent Technologies, Inc. (USA)
- Applied Biosystems Group (USA)
- AVIVA Biosciences Corporation (USA)
- Beckman Coulter, Inc. (USA)
- BG Medicine, Inc. (USA)
- BioForce Nanosciences, Inc. (USA)
- BioMarker Pharmaceuticals, Inc. (USA)
- Bristol Myers Squibb Co. (USA)
- Bruker Daltonics, Inc. (USA)
- Calibrant Biosystems, Inc. (USA)
- Caprion Pharmaceuticals, Inc. (Canada)
- Celera Genomics Group (USA)
- Correlogic Systems, Inc. (USA)
- Eli Lilly and Co. (USA)
- Fujirebio Diagnostics, Inc. (USA)
- Gene Logic, Inc. (Ore Pharmaceuticals, Inc.) (USA)
- GeneGo, Inc. (USA)
- GeneNews Ltd. (Canada)
- IBEX Technologies, Inc. (Canada)
- Iconix Biosciences, Inc. (USA)
- Large Scale Biology Corporation (USA)
- Metabolon, Inc. (USA)
- Monogram Biosciences, Inc. (USA)
- Pathwork Diagnostics (USA)
- PerkinElmer, Inc. (USA)
- Pfizer, Inc. (USA)
- SomaLogic, Inc. (USA)
- Thermo Fisher Scientific, Inc. (USA)
- Upstream Biosciences, Inc. (Canada)
- Vermillion, Inc. (formerly Ciphergen Biosystems) (USA)
- Therapeutic Area Analysis by Geographic Region
- Oncology
- Exhibit 25: Biomarkers in Oncology (2005-2012) - North American
Market Analysis (Current & Future) by Geographic Region for United
States and Canada in US$ Million (Graphical Representation Included)
- Exhibit 26: Biomarkers in Oncology (2006, 2009 and 2012) -
Percentage Breakdown of North American Market Value by Geographic Region
for United States and Canada (Graphical Representation Included)
- Cardiology
- Exhibit 27: Biomarkers in Cardiology (2005-2012) - North American
Market Analysis (Current & Future) by Geographic Region for United
States and Canada in US$ Million (Graphical Representation Included)
- Exhibit 28: Biomarkers in Cardiology (2006, 2009 and 2012) -
Percentage Breakdown of North American Market Value by Geographic Region
for United States and Canada (Graphical Representation Included)
- Neurology
- Exhibit 29: Biomarkers in Neurology (2005-2012) - North American
Market Analysis (Current & Future) by Geographic Region for United
States and Canada in US$ Million (Graphical Representation Included)
- Exhibit 30: Biomarkers in Neurology (2006, 2009 and 2012) -
Percentage Breakdown of North American Market Value by Geographic Region
for United States and Canada
- Other(Graphical Representation Included)
- Exhibit 31: Biomarkers in Other Therapeutics (2005-2012) - North
American Market Analysis (Current & Future) by Geographic Region for
United States and Canada in US$ Million (Graphical Representation
Included)
- Exhibit 32: Biomarkers in Other Therapeutics (2006, 2009 and 2012) -
Percentage Breakdown of North American Market Value by Geographic Region
for United States and Canada (Graphical Representation Included)
- Biomarker Discovery Technology Analysis by Geographic Region
- Imaging
- Exhibit 33: Imaging Technologies for Biomarker Discovery (2005-2012)
- North American Market Analysis (Current & Future) by Geographic Region
for United States and Canada in US$ Million (Graphical Representation
Included)
- Exhibit 34: Imaging Technologies for Biomarker Discovery (2006, 2009
and 2012) - Percentage Breakdown of North American Market Value by
Geographic Region United States and Canada (Graphical Representation
Included)
- Genomics
- Exhibit 35: Genomic Technologies for Biomarker Discovery (2005-2012)
- North American Market Analysis (Current & Future) by Geographic Region
for United States and Canada in US$ Million (Graphical Representation
Included)
- Exhibit 36: Genomic Technologies for Biomarker Discovery (2006, 2009
and 2012) - Percentage Breakdown of North American Market Value by
Geographic Region United States and Canada (Graphical Representation
Included)
- Proteomics
- Exhibit 37: Proteomic Technologies for Biomarker Discovery
(2005-2012) - North American Market Analysis (Current & Future) by
Geographic Region for United States and Canada in US$ Million (Graphical
Representation Included)
- Exhibit 38: Proteomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of North American Market Value by
Geographic Region United States and Canada(Graphical Representation
Included)
- Metabolomics
- Exhibit 39: Metabolomic Technologies for Biomarker Discovery
(2005-2012) - North American Market Analysis (Current & Future) by
Geographic Region for United States and Canada in US$ Million (Graphical
Representation Included)
- Exhibit 40: Metabolomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of North American Market Value by
Geographic Region United States and Canada(Graphical Representation
Included)
- Bioinformatics
- Exhibit 41: Bioinformatics for Biomarker Discovery (2005-2012) -
North American Market Analysis (Current & Future) by Geographic Region
for United States and Canada in US$ Million (Graphical Representation
Included)
- Exhibit 42: Bioinformatics for Biomarker Discovery (2006, 2009 and
2012) - Percentage Breakdown of North American Market Value by
Geographic Region United States and Canada(Graphical Representation
Included)
- Other
- Exhibit 43: Other Biomarker Discovery Technologies (2005-2012) -
North American Market Analysis (Current & Future) by Geographic Region
for United States and Canada in US$ Million (Graphical Representation
Included)
- Exhibit 44: Other Biomarker Discovery Technologies (2006, 2009 and
2012) - Percentage Breakdown of North American Market Value by
Geographic Region United States and Canada(Graphical Representation
Included)
- Europe
- Exhibit 45: Biomarkers (2005-2012) - European Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Major Companies in Europe
- ACE BioSciences A/S (Denmark)
- Affibody AB (Sweden)
- Alphalyse A/S (Denmark)
- Bayer AG (Germany)
- Biacore International AB (Sweden)
- BioSense Laboratories AS (Norway)
- Biotrin International (Ireland)
- BRAHMS AG (Germany)
- Dako A/S (Denmark)
- DxS Ltd. (UK)
- Epigenomics AG (Germany)
- GE Healthcare (UK)
- Genedata AG (Switzerland)
- GlaxoSmithKline Plc (UK)
- MDS Pharma Services (UK)
- Nonlinear Dynamics Ltd. (UK)
- Novartis AG (Switzerland)
- Oy Jurilab Ltd. (Finland)
- Proteome Sciences plc (UK)
- TheRyte Ltd. (UK)
- Therapeutic Area Analysis by Geographic Region
- Oncology
- Exhibit 46: Biomarkers in Oncology (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of
Europe in US$ Million (Graphical Representation Included)
- Exhibit 47: Biomarkers in Oncology (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe
- Cardiology
- Exhibit 48: Biomarkers in Cardiology (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of
Europe in US$ Million (Graphical Representation Included)
- Exhibit 49: Biomarkers in Cardiology (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe
- Neurology
- Exhibit 50: Biomarkers in Neurology (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of
Europe in US$ Million (Graphical Representation Included)
- Exhibit 51: Biomarkers in Neurology (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe
- Other
- Exhibit 52: Biomarkers in Other Therapeutics (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for Germany,
United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and
Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 53: Biomarkers in Other Therapeutics (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest
of Europe
- Biomarker Discovery Technology Analysis by Geographic Region
- Imaging
- Exhibit 54: Imaging Technologies for Biomarker Discovery (2005-2012)
- European Market Analysis (Current & Future) by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe in US$ Million (Graphical Representation
Included)
- Exhibit 55: Imaging Technologies for Biomarker Discovery (2006, 2009
and 2012) - Percentage Breakdown of European Market Value by Geographic
Region for Germany, United Kingdom, Italy, France, Spain, Switzerland,
Belgium, Sweden and Rest of Europe
- Genomics
- Exhibit 56: Genomic Technologies for Biomarker Discovery (2005-2012)
- European Market Analysis (Current & Future) by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe in US$ Million (Graphical Representation
Included)
- Exhibit 57: Genomic Technologies for Biomarker Discovery (2006, 2009
and 2012) - Percentage Breakdown of European Market Value by Geographic
Region for Germany, United Kingdom, Italy, France, Spain, Switzerland,
Belgium, Sweden and Rest of Europe
- Proteomics
- Exhibit 58: Proteomic Technologies for Biomarker Discovery
(2005-2012) - European Market Analysis (Current & Future) by Geographic
Region for Germany, United Kingdom, Italy, France, Spain, Switzerland,
Belgium, Sweden and Rest of Europe in US$ Million (Graphical
Representation Included)
- Exhibit 59: Proteomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of European Market Value by
Geographic Region for Germany, United Kingdom, Italy, France, Spain,
Switzerland, Belgium, Sweden and Rest of Europe
- Metabolomics
- Exhibit 60: Metabolomic Technologies for Biomarker Discovery
(2005-2012) - European Market Analysis (Current & Future) by Geographic
Region for Germany, United Kingdom, Italy, France, Spain, Switzerland,
Belgium, Sweden and Rest of Europe in US$ Million (Graphical
Representation Included)
- Exhibit 61: Metabolomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of European Market Value by
Geographic Region for Germany, United Kingdom, Italy, France, Spain,
Switzerland, Belgium, Sweden and Rest of Europe
- Bioinformatics
- Exhibit 62: Bioinformatics for Biomarker Discovery (2005-2012) -
European Market Analysis (Current & Future) by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe in US$ Million (Graphical Representation
Included)
- Exhibit 63: Bioinformatics for Biomarker Discovery (2006, 2009 and
2012) - Percentage Breakdown of European Market Value by Geographic
Region for Germany, United Kingdom, Italy, France, Spain, Switzerland,
Belgium, Sweden and Rest of Europe
- Other
- Exhibit 64: Other Biomarker Discovery Technologies (2005-2012) -
European Market Analysis (Current & Future) by Geographic Region for
Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe in US$ Million (Graphical Representation
Included)
- Exhibit 65: Other Biomarker Discovery Technologies (2006, 2009 and
2012) - Percentage Breakdown of European Market Value by Geographic
Region for Germany, UK, Italy, France, Spain, Switzerland, Belgium,
Sweden and Rest of Europe
- Asia-Pacific
- Exhibit 66: Biomarkers (2005-2012) -Asia-Pacific Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Major Companies in Asia-Pacific
- Human Metabolome Technologies, Inc. (Japan)
- Proteome Systems Ltd. (Australia)
- Soiken, Inc. (Japan)
- Triesta Sciences, Inc. (India)
- Therapeutic Area Analysis by Geographic Region
- Oncology
- Exhibit 67: Biomarkers in Oncology (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for China, India,
Australia and Rest of Asia-Pacific in US$ Million (Graphical
Representation Included)
- Exhibit 68: Biomarkers in Oncology (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for China, India, Australia and Rest of Asia-Pacific (Graphical
Representation Included)
- Cardiology
- Exhibit 69: Biomarkers in Cardiology (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for China,
India, Australia and Rest of Asia-Pacific in US$ Million (Graphical
Representation Included)
- Exhibit 70: Biomarkers in Cardiology (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for China, India, Australia and Rest of Asia-Pacific
- Neurology
- Exhibit 71: Biomarkers in Neurology (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for China,
India, Australia and Rest of Asia-Pacific in US$ Million (Graphical
Representation Included)
- Exhibit 72: Biomarkers in Neurology (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for China, India, Australia and Rest of Asia-Pacific (Graphical
Representation Included)
- Other
- Exhibit 73: Biomarkers in Other Therapeutics (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Geographic Region for
China, India, Australia and Rest of Asia-Pacific in US$ Million
(Graphical Representation Included)
- Exhibit 74: Biomarkers in Other Therapeutics (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for China, India, Australia and Rest of Asia-Pacific
- Biomarker Discovery Technology Analysis by Geographic Region
- Imaging
- Exhibit 75: Imaging Technologies for Biomarker Discovery
(2005-2012) - Asia-Pacific Market Analysis (Current & Future) by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
in US$ Million (Graphical Representation Included)
- Exhibit 76: Imaging Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
- Genomics
- Exhibit 77: Genomic Technologies for Biomarker Discovery
(2005-2012) - Asia-Pacific Market Analysis (Current & Future) by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
in US$ Million (Graphical Representation Included)
- Exhibit 78: Genomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
- Proteomics
- Exhibit 79: Proteomic Technologies for Biomarker Discovery
(2005-2012) - Asia-Pacific Market Analysis (Current & Future) by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
in US$ Million (Graphical Representation Included)
- Exhibit 80: Proteomic Technologies for Biomarker Discovery (2006,
2009 and 2012) - Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
- Metabolomics
- Exhibit 81: Metabolomic Technologies for Biomarker Discovery
(2005-2012) - Asia-Pacific Market Analysis (Current & Future) by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
in US$ Million (Graphical Representation Included)
- Exhibit 82: Metabolomic Technologies for Biomarker Discovery
(2006, 2009 and 2012) - Percentage Breakdown of Asia-Pacific Market
Value by Geographic Region for China, India, Australia and Rest of
Asia-Pacific
- Bioinformatics
- Exhibit 83: Bioinformatics for Biomarker Discovery (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Geographic Region
for China, India, Australia and Rest of Asia-Pacific in US$ Million
(Graphical Representation Included)
- Exhibit 84: Bioinformatics for Biomarker Discovery (2006, 2009 and
2012) - Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
- Other
- Exhibit 85: Other Biomarker Discovery Technologies (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Geographic Region
for China, India, Australia and Rest of Asia-Pacific in US$ Million
(Graphical Representation Included)
- Exhibit 86: Other Biomarker Discovery Technologies (2006, 2009 and
2012) - Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for China, India, Australia and Rest of Asia-Pacific
- Rest of World
- Exhibit 87: Biomarkers (2005-2012) - Rest of World Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Compugen Ltd. (Israel) - A Major Player
III. PRODUCT/TECHNOLOGY RESEARCH
- 1. Introduction
- Biomarkers Growth Trends - Global Markets
- Exhibit 88: Global Market for Biomarkers: Geographic Regions
(Asia-Pacific, Europe, Canada, Japan and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Biomarker Groups
- Biomarkers of Exposure
- Therapeutic Biomarkers
- Post Genomic Biomarker-Based Products Market
- Exhibit 89: Post Genomic Biomarker Based Products Market - Global
Estimates and Projections for the Period 2005-2012 in US$ Million
(Graphical Representation Included)
- Laboratory Process of Biomarkers Development
- F2-Isoprostances
- Reactive Oxygen and Nitrogen Species
- Biomarkers Associated with Breath Exhaled
- Application of Biomarkers
- Medical Sector
- Non-Medical Sector
- Categorization of Biomarkers
- DNA Biomarkers
- Mitochondrial DNA
- Inheritance of Mitochondria in Living Organisms
- Mitochondrion Transformations Lead to Cancer
- RNA Biomarkers
- Gene Biomarkers
- Metabolic Biomarkers
- Examining Degradation of Anerobic Hydrocarbon with Metabolic Biomarkers
- Cell Biomarkers
- Global Market for Cell Based Therapeutics
- Exhibit 90: Cell Based Therapeutics Market (2005-2012) - Global
Market Analysis (Current & Future) by Therapeutic Area for Central
Nervous System (CNS), Cancer Other in US$ Million (Graphical
Representation Included)
- Exhibit 91: Cell Based Therapeutics Market (2005-2012) - Percentage
Breakdown of Global Market Value by Therapeutic Area for Central Nervous
System (CNS), Cancer Other in US$ Million
- Single Nucleotide Polymorphism (SNP)
- Protein Biomarkers
- Upgrade of Proteins for Biomarkers
- Protein Biomarkers with Array Technologies
- Proteomic Studies to Enhance Drug Development Process
- Biomarkers and Molecular Diagnostics
- Systems Biology
- Aim of Systems Biology
- Omics Technologies based Systems Biology
- 2. Various Diseases - Role of Biomarkers
- Growth Trends - Global Biomarker Therapeutic Areas
- Exhibit 92: Global Market for Biomarkers: Major Biomarker Therapeutic
Areas (Cardiology, Neurology and Oncology) Ranked by Projected CAGR for
2005 through 2012 (Graphical Representation Included)
- Oncology
- Growth Trends - Global Market for Biomarkers in Oncology Therapeutics
- Exhibit 93: Global Market for Biomarkers in Oncology Therapeutics:
Geographic Regions (Asia- Pacific, Europe, Japan, Canada, United States)
Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation
Included)
- Application of biomarkers in Cancer Treatment
- Cancer Biomarkers
- Serum Biomarkers
- Prostate-Specific Antigen
- Other serum biomarkers
- Lung Cancer and Biomarkers
- Features of Biomarkers for Lung Cancer
- Breast and Ovarian Cancer
- Colorectal Cancer
- Hereditary Nonpolyposis Colorectal Cancer
- Mass Spectrometry - An Emerging Tool for Cancer Biomarker Discovery
- Role of Chromatography & Mass Spectrometry in Cancer Treatment
- Mass Spectrometry to Aid Laboratory Methods
- Global Marker for Mass Spectrometry
- Exhibit 94: Mass Spectrometry Market - Global Estimates and
Projections for the Period 2005-2012 in US$ Million (Graphical
Representation Included)
- Cardiology
- Growth Trends - Global Market for Biomarkers in Cardiology Therapeutics
- Exhibit 95: Global Market for Biomarkers in Cardiology Therapeutics:
Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- Cardiac Biomarkers - An Overview
- Renal Insufficiency-Risk of Cardiovascular Disease
- Global Market for Cardiovascular Diagnostics
- Exhibit 96: Cardiovascular Diagnostics Market - Global Estimates and
Projections for the Period 2005-2012 in US$ Million (Graphical
Representation Included)
- Neurology
- Growth Trends - Global Market for Biomarkers in Neurology Therapeutics
- Exhibit 97: Global Market for Biomarkers in Neurology Therapeutics:
Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- Neurodegenerative Diseases
- Global Neurodegerative Diseases Market
- Exhibit 98: Neurodegerative Diseases Market - Global Estimates and
Projections for the Period 2005-2012 in US$ Million (Graphical
Representation Included)
- Alzheimer' s
- Parkinson' s
- Huntington' s
- Traumatic Brain Injury
- Other
- Biomarkers for Detection of Arthritis
- Biomarkers in Gynecology
- Pre-Eclampsia in Women
- Protein Biomarker to Understand the Condition of Pre-Eclampsia
- Pre-Eclampsia' s and Oxidative Stress
- Role of Biomarkers of Oxidative Stress in Intricate Pregnancies
- Premenstrual Dysphoric Disorder
- Analysis of Premenstrual Dysphoric Disorder
- Premenstrual Syndrome
- Biomarkers in Analyzing Oxidative Stress
- Biomarkers to Analyze Oxidative Stress in Lung Disorders
- Tuberculosis
- Detection of Pulmonary Tuberculosis by Biomarkers
- Biomarkers for Detection of SARS Disease
- Role of Biomarkers in HIV Detection and Analysis
- Role of Biomarkers in Malaria Treatment
- Stage I
- Stage II
- Stage III or Key Stage
- Ageing Biomarkers
- Exhibit 99: Ageing Biomarkers and Their Effect
- Biomarkers for Detection of Renal Difficulties Leading To Diabetes
Mellitus
- Type 1 diabetes
- Type -2 diabetes
- 3. Biomarker Identification Technologies
- Growth Trends - Global Biomarker Therapeutic Areas
- Exhibit 100: Global Market for Biomarkers: Major Biomarker Discovery
Technologies (Bioinformatics, Genomics, Metabolomics, Proteomics and
Imaging) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- Imaging Technologies
- Imaging in Preclinical Studies
- Imaging Clinical Trials-Cancer
- Growth Trends - Global Imaging Technologies Market for Biomarkers
Discovery
- Exhibit 101: Global Market for Imaging Technologies for Biomarkers
Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and
United States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- Major Imaging Technologies
- Computer Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Diffusion MRI techniques
- Ultrasound or Sonography using MRI
- Magnetic Resonance Angiography (MRA)
- Magnetic Resonance Spectroscopy (MRS)
- Positron Emission Tomography (PET)
- Genomics
- Growth Trends - Global Genomics Market for Biomarkers Discovery
- Exhibit 102: Global Genomics Market for Biomarkers Discovery:
Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- Proteomics
- Growth Trends - Global Proteomics Market for Biomarkers Discovery
- Exhibit 103: Global Proteomics Market for Biomarkers Discovery:
Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- The Key Technologies that are used for Proteomics
- Matrix Assisted Laser Desorption Ionization (MALDI)
- Metabolomics
- Growth Trends - Global Metabolomics Market for Biomarkers Discovery
- Exhibit 104: Global Metabolomics Market for Biomarkers Discovery:
Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- The Crucial Role of Metabolomics in Discovery
- Biomarkers Discovery and Validation through Urinary Proteomics
- Bioinformatics
- Growth Trends - Global Bioinformatics Market for Biomarkers Discovery
- Exhibit 105: Global Bioinformatics Market for Biomarkers Discovery:
Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation Included)
- Other
- Fluorescent Indicators for Cancer Biomarkers and Neutral Sugars
- Identification of Biomarkers by Feature Wrappers
- Nanobiotechnology
- Biomarkers and Nanoproteins
- 4. Biomarkers in Drug Discovery/Development
- Biomarkers Application in Pharma Industry
- Nuclear Magnetic Resonance Techniques
- Mass Spectrometry Techniques to Aid the Study of Proteomics
- Genomics Techniques
- Metabolomics Techniques
- Devising and Monitoring of Biological Structure
- Devising of Sensors
- Data Base Management and Visualization Tools for Bioinformatics
- Inhalation Toxicology Techniques
- Varieties of Micro Arrays Employed in Pharmaceutical Sectors
- Eco Toxicology Techniques
- Why Pharma/Biotech Industry is Keen in Biomarkers?
- Application and Benefits of Biomarkers in Drug Development
- Verification of Biomarkers Applicability
- Biomarkers Application in Clinical Drug Development
- Biomarkers Effect on Discovery and Application of a Drug
- Drug Safety and Role of Biomarkers
- Toxic Biomarkers to Aid Drug Manufacture
- Toxicoproteomics
- PK/PD Biomarkers in Drug Development
- 5. Product Trends
- Enhanced Treatment for Spondylarthritis with Innovative Biomarkers
- A New Diagnostic Marker to Measure Efficiency of Cancer Drug
- SINE RNA to Emerge as Biomarker for Tobacco Hazards
- Kinetic Biomarker Enhances Drug Development
- New Biomarkers to Detect Nephrotoxicity
- Biomarkers in Combination with Pharmacogenomics
IV. MARKET DYNAMICS
- 1. Market Overview
- Global Market Analysis
- Exhibit 106: Biomarkers (2005-2012) - Global Market Analysis (Current
& Future) by Geographic Region for United States, Europe, Japan,
Asia-Pacific, Canada and Rest of World in US$ Million (Graphical
Representation Included)
- Exhibit 107: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Global Market Value by Geographic Region for United States, Europe,
Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation
Included)
- 2. Market Trends
- Biomarkers - An Emerging Trend in Pharma Industry
- Innovative Biomarker Discovery Methods Aid in Drug Development Stages
- Biomarkers Becoming Important in Developing Better Drugs
- Pharma Companies Investing Huge Amounts in Biomarkers Discovery
- What Pharma Companies Looking in Biomarkers?
- 3. Major Companies in Biomarker Industry
- Affibody AB (Sweden)
- Affymetrix, Inc. (USA)
- Agilent Technologies, Inc. (USA)
- Applied Biosystems Group (USA)
- AVIVA Biosciences Corporation (USA)
- Bayer AG (Germany)
- Beckman Coulter, Inc. (USA)
- BG Medicine, Inc. (USA)
- Biacore International AB (Sweden)
- BioForce Nanosciences, Inc. (USA)
- BioMarker Pharmaceuticals, Inc. (USA)
- BioSense Laboratories AS (Norway)
- Biotrin International (Ireland)
- BRAHMS AG (Germany)
- Bristol Myers Squibb Co. (USA)
- Bruker Daltonics, Inc. (USA)
- Calibrant Biosystems, Inc. (USA)
- Caprion Pharmaceuticals, Inc. (Canada)
- Celera Genomics Group (USA)
- Compugen Ltd. (Israel)
- Correlogic Systems, Inc. (USA)
- Dako A/S (Denmark)
- Diagnostics Products Corporation (USA)
- DxS Ltd. (UK)
- Eli Lilly and Co. (USA)
- Epigenomics AG (Germany)
- Fujirebio Diagnostics, Inc. (USA)
- GE Healthcare (UK)
- Gene Logic, Inc. (Ore Pharmaceuticals, Inc.) (USA)
- Genedata AG (Switzerland)
- Genego, Inc. (USA)
- GeneNews Ltd. (Canada)
- Human Metabolome Technologies, Inc. (Japan)
- IBEX Technologies, Inc. (Canada)
- Iconix Biosciences, Inc. (USA)
- Large Scale Biology Corporation (USA)
- MDS Pharma Services (UK)
- Metabolon, Inc. (USA)
- Monogram Biosciences, Inc. (USA)
- Nonlinear Dynamics Ltd. (UK)
- Novartis AG (Switzerland)
- Oy Jurilab Ltd. (Finland)
- Pathwork Diagnostics (USA)
- PerkinElmer, Inc. (USA)
- Pfizer, Inc. (USA)
- Proteome Sciences plc (UK)
- Proteome Systems Ltd. (Australia)
- Soiken, Inc. (Japan)
- SomaLogic, Inc. (USA)
- Thermo Fisher Scientific, Inc. (USA)
- TheRyte Ltd. (UK)
- Triesta Sciences, Inc. (India)
- Upstream Biosciences, Inc. (Canada)
- Vermillion, Inc. (formerly Ciphergen Biosystems) (USA)
- 4. Major Activities in Biomarker Industry
- GlaxoSmithKline Biologicals and OncoMethylome Sciences Collaborate for
Developing Personalized Cancer Treatment
- Biomarker Discovered by Korean Researchers to Help in Early Detection of
Cancer
- Singulex' s Biomarker Detection System used in Wyeth' s Research
- Proteome Sciences Introduces Tandem Mass Tag that Helps Overcome
Biomarker Validation Bottleneck
- Celera and Ipsen Enter Research Collaboration Agreement to Develop
Pharmacogenomic Tests
- Genedata Signs Japanese Research Initiative to Study Metastatic
Biomarkers
- Upstream Biosciences Introduces New Cheminformatics Program to Develop
New Drug Discovery Capabilities
- Banyan Biomarkers Starts International Clinical Trials for Detecting
Traumatic Brain Injury with Biomarkers
- Marshfield Clinic' s Warfarin Biomarker Licensed to Osmetech
- Siemens Medical Solutions Diagnostics and
B·R·A·H·M·S Agree to Develop
Procalcitonin (PCT) Assay on Siemens Immunoassay Platforms
- Fujirebio Diagnostics Granted Patent for Ovarian Cancer Biomarker
- Gene Logic Adopts New Corporate Identity
- Celera Completes Acquisition of Atria Genetics, Inc.
- Olink Bioscience and Applied Biosystems to Collaborate for
Commercializing Biomarker Validation Technology
- Strategic Alliance between GE Global Research, GE Healthcare and Eli
Lilly to Develop Molecular In-Vitro Diagnostics for Cancer Therapy
- BG Medicine Collaborates with Spinal Muscular Atrophy Foundation
- Vermillion (formerly Ciphergen) Publishes Protein Biomarker Research for
PAD
- Upstream Biosciences Acquires Pacific Pharma Technologies Inc.
- Ciphergen Adopts New Corporate Identity
- Upstream Biosciences Signs Agreement with Analytical Biological Services
to Provide Tissue Samples for Biomarker Validation
- Genedata Signs Agreement with Fiehn Laboratory for Refiner MS and
Analyst Software
- Proteome Systems Signs Agreement with BD to Develop Tuberculosis
Diagnostics
- New Collaboration between Partners HealthCare and Affymetrix for
Developing Personalized Medicine at a Faster Pace
- Upstream Biosciences Signs Agreement with Genpathway to Further
Biomarker Validation Studies
- Millipore Acquires Serologicals
- Dade Behring Receives Sublicense for using Beckman Counter' s New Cardiac
Biomarkers
- Monarch Lifesciences Enters into an Agreement with Genego to Provide
Pathway Analysis Services using 1-2-3 Workflow
- TIBCO Completes Acquisition of Spotfire
- Monarch LifeSciences™, the New Identity for INCAPS
- Roche Closes BioVeris Acquisition
- BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart
Failure from ACS Biomarker
- BG Medicine and Multiple Sclerosis Research Center of New York Announce
Collaboration
- BG Medicine Forms Research Collaboration with M. D. Anderson Cancer
Center
- Carestream Health Launched (Kodak Health Renamed as Carestream Health)
- New Collaboration Agreement between Affymetrix Clinical Services Lab,
Agencourt, and NuGEN Technologies for Blood Sample Expression Profiling with
GeneChip(R) Microarrays
- Boehringer Ingelheim Expands License with GeneGo to Global Scale
- Upstream Biosciences Inc. Signs Agreement with NimbleGen Systems Inc.
for Biomarker Validation Studies
- Compugen Enters into Second Diagnostic Agreement with Biosite
- Lipomics and Agilent Technologies Collaborate on Research and
Development of Diagnostic Biomarker Assays
- Compugen to Collaborate with Teva for Discovery of Novel Biomarkers for
Drug Toxicity
- Illumina Acquires Complete Stake in Solexa
- BG Medicine and Applied Biosystems to Collaborate on Molecular Medicine
Research
- Epigenomics AG Joins Hands with Centocor Inc. to Discover Biomarkers
- Siemens Medical Solutions Acquires Bayer' s Healthcare Diagnostic Division
- BD Acquires TriPath
- Genetix Acquires Applied Imaging Corp
- Bruker Daltonics Expands Biomarker Discovery Collaboration with
HealthLinx
- Rules-Based Medicine Merges with Multiplex Biosciences
- Bio-Rad Acquires Ciphergen' s Life Science Business
- Caprion Pharmaceuticals and Vertex Pharmaceuticals Expand Biomarker
Discovery Collaboration
- Iconix Changes Corporate Identity
- Lumera Extends Collaboration with Institute for Systems Biology
- Tandem Labs Takes Over PharmaKD
- Axela Collaborates with Abnova to Develop Biomarker Panels
- Genstruct Extends Agreement GlaxoSmithKline
- Epigenomics AG Signs R&D Agreement with Johnson & Johnson
- Siemens Acquires Diagnostic Products Corp
- PerkinElmer and University of Leicester Sign Research Agreement
- Asterand Enters into Partnership with Rubicon
- Applied Biosystems Collaborates with SAIC-Frederick
- PPD Signs Agreement with PDL BioPharma
- ART Acquires Alerion Biomedical
- Varian Acquires IonSpec Corp.
- BD Takes Over GeneOhm
- Cytomyx Partners with OrigGene
- Merck Signs Agreement with FoxHollow Technologies
- Wyeth Expands Collaboration with Caprion
- Compugen Enters into Collaboration with Ortho-Clinical Diagnostics
- BioSystems International Signs Agreement with Euroscreen
- PPD Takes Over SurroMed
- 5. Major Product Innovations/Launches in Biomarker Industry
- BioServe Introduces ControlMATCH for Improving Biomarker Validation
- Metabolon Launches New mVision™ for Biomarker Discovery
- New Human-14 Protein Removal System Introduced by Agilent Technologies
- New Tools for Biomarker Research from Applied Biosystems and MDS' Sciex
- PerkinElmer Introduces New Assay Development Service for Homogenous
ELISA Conversions
- Genedata Launches New Expressionist for Enhanced Cross-Omics Technology
Integration in Biomarker Discovery
- Fluidigm Launches Biomark™ System
- OXIS Launches New Reagents and Antibodies
- OGeS and Oxford University Develop Novel Biomarkers
- ART Launches Fenestra™
- Agilent Launches Liquid Chromatography (LC) Column
- Bruker Daltonics Launches Molecular Imager
- Waters Enhances ProteinLynx
- Beckman Coulter Upgrades ProteomeLab™
- GeneData Launches Expressionist® Pro 3.0
- GenoLogics Enhances ProteusLIMS™
- Nonlinear Launches Progenesis PG600
- Bruker Daltonics Upgrades ClinProt™
- PekinElmer Launches BioXPRESSION™
- BioGenex Unveils Xmatrx
- Waters Introduces MassTrak Clinical Solutions
- Bruker Daltonics Launches Clinical Proteomics System
- Fujirebio Diagnostics Introduces Blood Test for Mesothelioma
- 6. Regional Market Analysis
- A. The United States
- Market Analysis
- Exhibit 108: Biomarkers (2005-2012) - United States Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 109: List of Major Companies in the United States
- Analysis by Therapeutic Area
- Exhibit 110: Biomarkers (2005-2012) - United States Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 111: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of United States Market Value by Therapeutic Area for Oncology,
Cardiology, Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 112: Biomarkers (2005-2012) - United States Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 113: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of United States Market Value by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics, Bioinformatics and Other
- B. Europe
- Market Analysis
- Exhibit 114: Biomarkers (2005-2012) - European Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 115: List of Major Companies in Europe
- Analysis by Geographic Region
- Exhibit 116: Biomarkers (2005-2012) - European Market Analysis
(Current & Future) by Geographic Region for Germany, United Kingdom,
Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in
US$ Million (Graphical Representation Included)
- Exhibit 117: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of European Market Value by Geographic Region for Germany, United
Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of
Europe
- Analysis by Therapeutic Area
- Exhibit 118: Biomarkers (2005-2012) - European Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 119: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of European Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 120: Biomarkers (2005-2012) - European Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 121: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of European Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- European Biomarkers Market By Country
- B1. Germany
- German Market Analysis
- Analysis by Therapeutic Area
- Exhibit 122: Biomarkers (2005-2012) - German Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 123: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of German Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 124: Biomarkers (2005-2012) - German Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 125: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of German Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B2.The United Kingdom
- UK Market Analysis
- Analysis by Therapeutic Area
- Exhibit 126: Biomarkers (2005-2012) - United Kingdom Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 127: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of United Kingdom Market Value by Therapeutic Area for Oncology,
Cardiology, Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 128: Biomarkers (2005-2012) - United Kingdom Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 129: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of United Kingdom Market Value by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics, Bioinformatics and Other
- B3. Italy
- Italian Market Analysis
- Analysis by Therapeutic Area
- Exhibit 130: Biomarkers (2005-2012) - Italian Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 131: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Italian Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 132: Biomarkers (2005-2012) - Italian Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 133: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Italian Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B4. France
- French Market Analysis
- Analysis by Therapeutic Area
- Exhibit 134: Biomarkers (2005-2012) - French Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 135: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of French Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 136: Biomarkers (2005-2012) - French Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 137: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of French Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B5. Spain
- Spanish Market Analysis
- Analysis by Therapeutic Area
- Exhibit 138: Biomarkers (2005-2012) - Spanish Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 139: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Spanish Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 140: Biomarkers (2005-2012) - Spanish Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other (Graphical
Representation Included)
- Exhibit 141: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Spanish Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B6. Switzerland
- Swiss Market Analysis
- Analysis by Therapeutic Area
- Exhibit 142: Biomarkers (2005-2012) - Swiss Market Analysis (Current
& Future) by Therapeutic Area for Oncology, Cardiology, Neurology and
Other in US$ Million (Graphical Representation Included)
- Exhibit 143: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Swiss Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 144: Biomarkers (2005-2012) - Swiss Market Analysis (Current
& Future) by Discovery Technology for Imaging, Genomics, Proteomics,
Metabolomics, Bioinformatics and Other in US$ Million (Graphical
Representation Included)
- Exhibit 145: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Swiss Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B7. Belgium
- Belgian Market Analysis
- Analysis by Therapeutic Area
- Exhibit 146: Biomarkers (2005-2012) - Belgian Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 147: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Belgian Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 148: Biomarkers (2005-2012) - Belgian Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 149: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Belgian Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B8. Sweden
- Swedish Market Analysis
- Analysis by Therapeutic Area
- Exhibit 150: Biomarkers (2005-2012) - Swedish Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 151: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Swedish Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 152: Biomarkers (2005-2012) - Swedish Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 153: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Swedish Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- B9. Rest of Europe
- Rest of Europe Market Analysis
- Analysis by Therapeutic Area
- Exhibit 154: Biomarkers (2005-2012) - Rest of Europe Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 155: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Rest of Europe Market Value by Therapeutic Area for Oncology,
Cardiology, Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 156: Biomarkers (2005-2012) - Rest of Europe Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 157: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Rest of Europe Market Value by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics, Bioinformatics and Other
- C. Japan
- Market Analysis
- Exhibit 158: Biomarkers (2005-2012) - Japanese Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 159: List of Major Companies in Japan
- Analysis by Therapeutic Area
- Exhibit 160: Biomarkers (2005-2012) - Japanese Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 161: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Japanese Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other (Graphical Representation Included)
- Analysis by Biomarker Discovery Technology
- Exhibit 162: Biomarkers (2005-2012) - Japanese Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 163: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Japanese Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- D. Asia-Pacific
- Market Analysis
- Exhibit 164: Biomarkers (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 165: List of Major Companies in Asia-Pacific
- Analysis by Geographic Region
- Exhibit 166: Biomarkers (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) by Geographic Region for China, India, Australia and
Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 167: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Asia-Pacific Market Value by Geographic Region for China, India,
Australia and Rest of Asia-Pacific (Graphical Representation Included)
- Analysis by Therapeutic Area
- Exhibit 168: Biomarkers (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 169: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Asia-Pacific Market Value by Therapeutic Area for Oncology,
Cardiology, Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 170: Biomarkers (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 171: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Asia-Pacific Market Value by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics, Bioinformatics and Other
- Asia-Pacific Biomarkers Market By Country
- D1. China
- Chinese Market Analysis
- Analysis by Therapeutic Area
- Exhibit 172: Biomarkers (2005-2012) - Chinese Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 173: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Chinese Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 174: Biomarkers (2005-2012) - Chinese Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 175: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Chinese Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- D2. India
- Indian Market Analysis
- Analysis by Therapeutic Area
- Exhibit 176: Biomarkers (2005-2012) - Indian Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 177: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Indian Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 178: Biomarkers (2005-2012) - Indian Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 179: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Indian Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- D3. Australia
- Australian Market Analysis
- Analysis by Therapeutic Area
- Exhibit 180: Biomarkers (2005-2012) - Australian Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 181: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Australian Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 182: Biomarkers (2005-2012) - Australian Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 183: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Australian Market Value by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics
- D4. Rest of Asia-Pacific
- Rest of Asia-Pacific Market Analysis
- Analysis by Therapeutic Area
- Exhibit 184: Biomarkers (2005-2012) - Rest of Asia-Pacific Market
Analysis (Current & Future) by Therapeutic Area for Oncology,
Cardiology, Neurology and Other in US$ Million (Graphical Representation
Included)
- Exhibit 185: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Rest of Asia-Pacific Market Value by Therapeutic Area for Oncology,
Cardiology, Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 186: Biomarkers (2005-2012) - Rest of Asia-Pacific Market
Analysis (Current & Future) by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$
Million (Graphical Representation Included)
- Exhibit 187: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Rest of Asia-Pacific Market Value by Discovery Technology for
Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
- E. Canada
- Market Analysis
- Exhibit 188: Biomarkers (2005-2012) - Canadian Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 189: List of Major Companies in Canada
- Analysis by Therapeutic Area
- Exhibit 190: Biomarkers (2005-2012) - Canadian Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 191: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Canadian Market Value by Therapeutic Area for Oncology, Cardiology,
Neurology and Other(Graphical Representation Included)
- Analysis by Biomarker Discovery Technology
- Exhibit 192: Biomarkers (2005-2012) - Canadian Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 193: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Canadian Market Value by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other
- F. Rest of World
- Market Analysis
- Exhibit 194: Biomarkers (2005-2012) - Rest of World Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 195: List of Major Companies in Rest of World
- Analysis by Therapeutic Area
- Exhibit 196: Biomarkers (2005-2012) - Rest of World Market Analysis
(Current & Future) by Therapeutic Area for Oncology, Cardiology,
Neurology and Other in US$ Million (Graphical Representation Included)
- Exhibit 197: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Rest of World Market Value by Therapeutic Area for Oncology,
Cardiology, Neurology and Other
- Analysis by Biomarker Discovery Technology
- Exhibit 198: Biomarkers (2005-2012) - Rest of World Market Analysis
(Current & Future) by Discovery Technology for Imaging, Genomics,
Proteomics, Metabolomics, Bioinformatics and Other in US$ Million
(Graphical Representation Included)
- Exhibit 199: Biomarkers (2006, 2009 and 2012) - Percentage Breakdown
of Rest of World Market Value by Discovery Technology for Imaging,
Genomics, Proteomics, Metabolomics Bioinformatics and Other
- 7. Biomarkers - The Industry Outlook
V. CORPORATE DIRECTORY
|
|
|
|
|
|
|
[Report]
BIOMARKERS - A MARKET INSIGHT REPORT
Published: 2008/01
|
Published by : RI Technologies  |
|
|
Price:
|
Product Code : RIT63058 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
